Peptide Drugs Reverse Mitochondrial Damage in Friedreich Ataxia — But Reveal a Therapeutic Catch | Research

The takeaway

The peptides TAT-P110 and SS-31 both reversed mitochondrial fragmentation in Friedreich ataxia cells through Drp1-dependent mechanisms, but TAT-P110 decreased ATP levels while SS-31 did not — revealing that fragmentation may be a beneficial compensatory response.

Helpful damage?
Mitochondrial fragmentation in Friedreich ataxia may actually be helping cells maintain energy — reversing it with TAT-P110 decreased ATP, while SS-31 avoided this problem

What the researchers found

TAT-P110 and SS-31 both reversed Drp1-dependent mitochondrial fragmentation in FRDA cells. TAT-P110 decreased ATP levels (suggesting fragmentation is homeostatic). SS-31 reversed fragmentation without affecting ATP. Both act through the same pathway with different downstream effects.

Why it matters

This study reveals a critical nuance for mitochondrial disease therapy: not all mitochondrial "damage" should be reversed. Some morphological changes are the cell's way of coping. Therapies must distinguish beneficial compensation from harmful dysfunction.

The numbers in context

TAT-P110 reversed fragmentation + decreased ATP; SS-31 reversed fragmentation without ATP drop; Drp1-dependent; combination = SS-31 alone

How the study worked

In vitro study. Frataxin-knockdown fibroblasts and FRDA patient fibroblasts. Drp1 inhibition by TAT-P110 peptide. Cardiolipin stabilization by SS-31 peptide. Mitochondrial morphology, Drp1 activity, and ATP levels measured. Drug combination testing.

Who was studied

Frataxin-knockdown fibroblasts and FRDA patient fibroblasts

What this study cannot tell us

In vitro fibroblast study — neuronal and cardiac cells (most affected in FRDA) may respond differently. ATP measurement is one bioenergetic parameter. Long-term effects and functional outcomes not assessed.

How to read the evidence

Moderate evidence: patient-derived fibroblast data with mechanistic analysis, but in vitro only.

When this study was published

Published 2021. SS-31 (elamipretide) is in clinical development for mitochondrial diseases.

The bigger picture

This has implications beyond Friedreich ataxia. Many neurodegenerative diseases show mitochondrial fragmentation, and drugs to reverse it are being developed. This study warns that blindly reversing fragmentation could impair compensatory energy production.

Questions still open

Would SS-31 improve symptoms in Friedreich ataxia patients where TAT-P110 might not?
Does the homeostatic fragmentation principle apply to other neurodegenerative diseases like Parkinson's?
Can mitochondrial fragmentation be selectively reversed in disease-relevant tissues?

Common questions

What is Friedreich ataxia?

Friedreich ataxia is a genetic disease caused by loss of frataxin, a mitochondrial protein. It causes progressive nerve damage, heart problems, and coordination loss. There is currently no approved treatment, though peptide drugs like SS-31 are being investigated.

Could SS-31 help Friedreich ataxia patients?

SS-31 (elamipretide) reversed mitochondrial damage in FRDA cells without depleting energy — a better profile than TAT-P110. SS-31 is in clinical development for mitochondrial diseases, and this study supports its potential for FRDA. Clinical trials would be needed to confirm benefit.

Read the original research

Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.

Pharmacology research & perspectives, 9(3), e00755

View on PubMed ↗Publisher’s paper ↗

Citation

Johnson, Joseph; Mercado-Ayón, Elizabeth; Clark, Elisia; Lynch, David; Lin, Hong. (2021). Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.. Pharmacology research & perspectives, 9(3), e00755. https://doi.org/10.1002/prp2.755